The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis.

Br J Clin Pharmacol 2013 Dec;76(6):939-45

Department of Pharmacy, Sint Maartenskliniek, Nijmegen, the Netherlands.

Aim: Early prediction of (non-)response to infliximab therapy can improve therapeutic benefit by avoiding unnecessary periods of high disease activity during ineffective therapy. This prospective cohort study therefore aimed to study the predictive value of (1) disease activity alone and (2) infliximab serum trough concentrations in addition to disease activity 6 weeks after start of treatment for achieving low disease activity after 6 months.

Methods: Disease activity and infliximab serum trough concentrations were assessed in all rheumatoid arthritis (RA) patients at 2, 6 and 26 weeks after initiation of infliximab therapy. Receiver operating characteristic (ROC) curves and Youden indices were used to calculate specificity for prediction of good response after 6 months while aiming for maximum sensitivity.

Results: Fifty-seven consecutive RA patients starting with infliximab therapy were included. After 6 months, 15 (26%, 95 % CI 15, 38%) patients reached good European League against Rheumatism (EULAR) response. A disease activity score <4.2 at 6 weeks after initiation of therapy was a moderate predictor for reaching EULAR response after 6 months (sensitivity 100%, specificity 49%). Infliximab serum trough concentrations (>2.5 mg l(-1)) as predictor complimentary to disease activity (<4.2) slightly increased the specificity from 49% to 54% without changing the sensitivity (100%). As 39% of the patients did not fulfill at least one of these criteria at week 6, these patients could already be switched to another therapy after 6 weeks.

Conclusions: The combination of disease activity and infliximab serum trough concentrations could be a fair predictor to identify early (after 6 weeks) patients who have insufficient response after 6 months of therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845317PMC
December 2013
25 Reads

Publication Analysis

Top Keywords

disease activity
32
serum trough
12
activity infliximab
12
trough concentrations
12
infliximab therapy
12
infliximab serum
12
non-response infliximab
8
rheumatoid arthritis
8
early prediction
8
prediction non-response
8
activity
8
disease
7
infliximab
7
arthritis patients
4
assessed rheumatoid
4
concentrations assessed
4
concentrations addition
4
patients weeks
4
therapy receiver
4
initiation infliximab
4

References

(Supplied by CrossRef)

Similar Publications